Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Kyorin Pharmaceutical reports novel AMPK activators

March 26, 2012

Applications submitted for once-monthly risedronate sodium hydrate in Japan

March 26, 2012

Byetta obtains European approval as add-on therapy to basal insulin

March 26, 2012

Toray evaluates 11-beta-HSD1 inhibitor in obesity and diabetes models

March 26, 2012

Hyperion Therapeutics acquires rights to Ravicti

March 26, 2012

Daiichi Sankyo seeks line extension for denosumab in Japan

March 23, 2012

Corcept Therapeutics announces launch plan

March 23, 2012

Taisho presents novel sodium/glucose cotransporter 1 inhibitors

March 23, 2012

Novel GPR119 receptor agonists prepared by Lupin

March 23, 2012

New product has antidiabetic and antiobesity effects in various animal models

March 23, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...